<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227097</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 02 03</org_study_id>
    <nct_id>NCT00227097</nct_id>
  </id_info>
  <brief_title>Educ'Avk: Recommendations for the Antivitamin K's Gestion</brief_title>
  <official_title>Implication of Patient in the Making Ready of Recommendations for the Antivitamin K's Gestion in Case of Thrombosis Embolic Venous's Illness. Randomised Study for Clinical Validation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <brief_summary>
    <textblock>
      The objective of the project &quot;Educ'Avk&quot;, is to document the efficacy of a strategy combining&#xD;
      a specific follow up-notebook and education of attending patient with a pedagogic support,&#xD;
      comparatively to an usual education on the impact of clinical events at three months (minor&#xD;
      or major hemorrhagic events + recurrence of thrombi-embolic's disease).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard strategies for the implementation of recommendations are exclusively focused on&#xD;
      practitioners. But often they do not appear to be effective (insufficient time accorded per&#xD;
      patient, lack of training…).&#xD;
&#xD;
      However some qualitative surveys have shown the benefit of a greater role on the part patient&#xD;
      in the process of transmitting recommendations through the practitioner.&#xD;
&#xD;
      In this study, patient education is begun by the angiologist or a pharmacy student under the&#xD;
      responsibility of the hospital investigator. Follow-up is realized by the patient's general&#xD;
      practitioner.&#xD;
&#xD;
      More patient involvement in the realization of the recommendations could increase the&#xD;
      proportion of practitioners who follow the recommendations and decrease the iatrogenicity of&#xD;
      antivitamin K (AVK).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2002</start_date>
  <completion_date>December 2004</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>AVK Treatment</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Education Notebook for anticoagulant treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to receive benefit sanitary educational act&#xD;
&#xD;
          -  Able to be followed up during three months&#xD;
&#xD;
          -  Acute episode of a venous's thrombi embolic illness (venous's thrombosis distal or&#xD;
             proximal deep and/or lung embolism)&#xD;
&#xD;
          -  A.V.K. treatment for a period of at least three months&#xD;
&#xD;
          -  Return to residence (included return to retreat residence no medicalize)&#xD;
&#xD;
          -  Informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distal venous thrombosis limited muscular vein without lung embolism&#xD;
&#xD;
          -  Contra-indication of to an A.V.K. treatment&#xD;
&#xD;
          -  Difficult comprehension of the french language&#xD;
&#xD;
          -  Trouble of visual acuity&#xD;
&#xD;
          -  Trouble of superior function incompatible with an educational's act sanitary&#xD;
&#xD;
          -  Psycho-social instability incompatible with a regular follow-up of three months&#xD;
             (without fixed residence, addictive lapsed)&#xD;
&#xD;
          -  Impossibility to return to residence (the return in retreat residence no medicalize is&#xD;
             considered as a return to residence)&#xD;
&#xD;
          -  Psychiatric pathology not compensated&#xD;
&#xD;
          -  Life expectancy less than three months&#xD;
&#xD;
          -  Refusal of participation in the study&#xD;
&#xD;
          -  Participation in another clinical study&#xD;
&#xD;
          -  Anterior inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc BOSSON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Departement - University Hospital of Grenoble - BP 217</name>
      <address>
        <city>La tronche</city>
        <state>Grenoble Cédex 9</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gratacap-Cavallier B, Bosson JL, Morand P, Dutertre N, Chanzy B, Jouk PS, Vandekerckhove C, Cart-Lamy P, Seigneurin JM. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol. 1998 Feb;14(2):147-52.</citation>
    <PMID>9556173</PMID>
  </reference>
  <reference>
    <citation>Bertrand D, François P, Bosson JL, Fauconnier J, Weil G. Quality assessment of discharge letters in a French university hospital. Int J Health Care Qual Assur Inc Leadersh Health Serv. 1998;11(2-3):90-5.</citation>
    <PMID>10185321</PMID>
  </reference>
  <reference>
    <citation>Mezin P, Payen JF, Bosson JL, Brambilla E, Stieglitz P. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br J Anaesth. 1997 Sep;79(3):327-31.</citation>
    <PMID>9389850</PMID>
  </reference>
  <reference>
    <citation>Payen JF, Bosson JL, Bourdon L, Jacquot C, Le Bas JF, Stieglitz P, Benabid AL. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy. Anesthesiology. 1993 May;78(5):848-55.</citation>
    <PMID>8489056</PMID>
  </reference>
  <reference>
    <citation>Vermont J, Bosson JL, François P, Robert C, Rueff A, Demongeot J. Strategies for graphical threshold determination. Comput Methods Programs Biomed. 1991 Jun;35(2):141-50.</citation>
    <PMID>1914452</PMID>
  </reference>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>July 6, 2006</last_update_submitted>
  <last_update_submitted_qc>July 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2006</last_update_posted>
  <keyword>therapeutic education</keyword>
  <keyword>thrombi embolic disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

